Advanced Therapy Medicinal Products Market Analysis

Disease (Oncology, Genetic Disorder, CNS, Dermatology)

The global advanced therapy medicinal products market is segmented and analyzed for demand and supply by disease into oncology, genetic disorder, CNS, dermatology, and others. Out of all, the dermatology segment is to garner the highest revenue at the end of 2037, growing at a CAGR of 12.5% over the forecast period. The segment growth is expected on the back of rising cases of skin problems and cancer in the world. According to the World Health Organization, currently, 132,000 cases of melanoma and 2 to 3 million cases of non-melanoma skin cancer are reported annually worldwide. Skin cancer accounts for one in three cancer diagnoses, and one in five Americans will have it at some point in their lives.

Product (CAR-T Therapy, Gene Therapy, Cell Therapy, Tissue Engineered Product)

The global advanced therapy medicinal products market is also segmented and analyzed for demand and supply by product into CAR-T therapy, gene therapy, cell therapy, and tissue-engineered product. Amongst these four segments, the gene therapy segment is expected to grow at a CAGR of 13.8% over the forecast period. The segment growth is expected on the back of a higher number of people in need of gene therapy and growing clinical trials of gene therapy. By 2034, gene therapies could be used to treat more than 1 million Americans. Furthermore, in 2022, around 1221 cell and gene therapies are under active clinical trials, moreover, out of them nearly 324 clinical trials are in the phase of 1/1b.

Our in-depth analysis of the global market includes the following segments: